Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
738.67B
Market cap738.67B
Price-Earnings ratio
63.84
Price-Earnings ratio63.84
Dividend yield
0.73%
Dividend yield0.73%
Average volume
3.40M
Average volume3.40M
High today
$784.44
High today$784.44
Low today
$763.02
Low today$763.02
Open price
$772.89
Open price$772.89
Volume
2.79M
Volume2.79M
52 Week high
$972.53
52 Week high$972.53
52 Week low
$677.09
52 Week low$677.09

LLY News

Simply Wall St 2d
Eli Lilly Advances Orforglipron GLP-1 Therapy To Phase 3 With Positive Results

recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 receptor agonist showing superior A1C reduction in type...

Eli Lilly Advances Orforglipron GLP-1 Therapy To Phase 3 With Positive Results
Sherwood News 4d
Eli Lilly slips after UK declines to cover Alzheimer’s drug

Eli Lilly slips after UK declines to cover Alzheimer’s drug Eli Lilly fell about 3% on Friday after the United Kingdom’s national health provider said it would...

Eli Lilly slips after UK declines to cover Alzheimer’s drug
Simply Wall St 5d
Eli Lilly Faces $7 Billion Lawsuit While Partnering With Innovative Biotech

has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out am...

Eli Lilly Faces $7 Billion Lawsuit While Partnering With Innovative Biotech

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
9.7%
Sell
6.5%

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.